Pharmacogenomics: where does Britain stand?

By Hudson John  

Pharmacogenomics, Vol. 13, Iss. 1, 2012-01 ,pp. : 1-3

Future Medicine

Access to resources Recommend Favorite

Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going?

By Yamamoto Norio   Tsuchiya Hiroyuki  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 16, 2013-11 ,pp. : 2183-2193

Informa Healthcare

Access to resources Recommend Favorite

From adefovir to Atripla™ via tenofovir, Viread™ and Truvada™

By De Clercq Erik  

Future Virology, Vol. 1, Iss. 6, 2006-11 ,pp. : 709-715

Future Medicine

Access to resources Recommend Favorite

Biochemical characterisation of newly developed -etorphine and -dihydroetorphine derivatives

By Biyashev D.   Garadnay S.   Marton J.   Makleit S.   Borsodi A.   Benyhe S.  

European Journal of Pharmacology, Vol. 442, Iss. 1, 2002-05 ,pp. : 23-27

Elsevier

Access to resources Recommend Favorite

Statins in Heart Failure—Where Do We Stand?

By Lyons Kristopher   McVeigh Gary   Harbinson Mark  

Cardiovascular Drugs and Therapy, Vol. 25, Iss. 1, 2011-02 ,pp. : 99-104

Springer Publishing Company

Access to resources Recommend Favorite